Gene transfer to the major salivary glands is an attractive method for the systemic delivery of therapeutic proteins. To date, nonviral gene transfer to these glands has resulted in inadequate systemic protein concentrations. We believe that identification of the barriers responsible for this inefficient transfection will enable the development of enhanced nonviral gene transfer in salivary glands and other tissues. One potential barrier is the degradation of plasmid DNA by endonucleases. To test this hypothesis, we coadministered two endonuclease inhibitors ((zinc and aurintricarboxylic acid (ATA)) with plasmid DNA, containing the secreted alkaline phosphatase gene (SEAP), to the submandibular glands of rats. The effect of zinc and ATA on SEAP expression, tissue accumulation of plasmid DNA, and plasmid DNA stability was then characterized. We observed that mixtures containing zinc/DNA, ATA/DNA, and zinc/ATA/DNA significantly enhanced both systemic transgene expression and the amount of plasmid DNA associated with treated tissues. The relative endonuclease inhibitory activity of zinc, ATA, and zinc/ATA correlated with the observed effects on transfection efficacy. The use of zinc/ATA enhanced the efficacy of salivary gland transfection by at least 1000-fold versus DNA alone. Importantly, this improved performance resulted in robust systemic secretion of an exogenous protein (SEAP), thus demonstrating the potential this nonviral gene transfer technology has as a method to treat systemic protein deficiencies.
Introduction
The administration of gene-based therapeutics to the salivary glands (SGs) is an effective method to generate systemic protein expression. Although these glands primarily secrete proteins into the saliva, they also secrete substantial quantities of proteins into the bloodstream. 1 This observation has been exploited to produce systemic release of protein encoded by a transgene. For instance, the administration of an adenovirus encoding human growth hormone protein to the SG resulted in systemic protein expression. [2] [3] [4] [5] More recently, we have demonstrated that systemic protein expression can also be obtained with nonviral DNA formulations. 6 Although administration of viral-based vectors to the SGs of experimental animals results in therapeutic concentrations of protein in blood, the recent complications that have occurred in clinical studies have increased concerns about the general safety of viral technologies. 7, 8 In the light of these developments, nonviral formulations are a more appealing alternative to viral-based vectors. In addition, nonviral vectors are cheaper and easier to manufacture. Unfortunately, SG transfection with nonviral formulations has failed to generate systemic transgene expression at clinically relevant levels. For example, treatment of SGs with a state-of-the-art lipoplex formulation resulted in systemic human growth hormone (hGH) concentrations o100 pg/ml in serum, a concentration 100-fold lower than that observed using adenovirus. 9 It is clear that novel methods for nonviral transfection are needed before systemic diseases can be effectively treated using this gene transfer approach. We believe that elucidation of the barriers to efficient salivary gland transfection will enable the development of such methods.
The degradation of plasmid DNA by endonucleases is one potential barrier to efficient transfection. The concentration of deoxyribonucleases (DNases) found in the salivary gland is generally substantially higher than the concentration found in other tissues. 6, 10 Recently, we have discovered that zinc and other divalent metals enhance local and systemic gene expression following retroductal administration of metal/plasmid DNA formulations to the submandibular gland. 6 Although the mechanism for the observed transfection enhancement is likely to be multifaceted, our results indicated that endonuclease inhibition may be responsible, at least in part. Preliminary studies in our laboratories have shown that aurintricarboxylic acid (ATA), a known nuclease inhibitor, also enhances SG transfection. In this paper, we expand on this observation and provide additional experimental evidence supporting the hypothesis that endogenous nucleases are a significant barrier to efficient nonviral SG transfection. In addition, we have identified and optimized a novel zinc/ATA/DNA formulation that improves SG transfection efficacy, possibly by traversing this barrier. Based on transfection activity and safety (histology) studies presented herein and others (not published), we conclude that administration of a solution (50 ml) containing 300 mg of pDNA (SEAP), 3.6 mM zinc chloride, and 8 mg/ml ATA is optimal for rat submandibular gland transfection.
Results
Zinc/ATA mixtures enhance transgene expression after nonviral SG transfection
Our previous study has demonstrated that the addition of zinc chloride to a plasmid DNA formulation increases transgene expression in salivary gland tissues by 20-fold relative to a plasmid DNA-only solution. 6 It was hypothesized that this increased transfection activity may be attributed to zinc-mediated inhibition of DNase activity. ATA, another known DNase inhibitor, was evaluated in this context. ATA, zinc, and zinc/ATA solutions were formulated with plasmid DNA and administered to the SGs. The relative transfection efficiency of these formulations, determined by measuring the levels of transgene expression, was compared to the transfection efficiency of a plasmid DNA-only solution. As shown in Figure 1 , the addition of either zinc or ATA to plasmid DNA solutions increased observed SEAP concentration in plasma. The highest average plasma level of SEAP protein (44 ng/ml) was observed after treatment with the zinc/ATA/DNA formulation, which suggests a synergistic zinc/ATA/ DNA interaction. The zinc concentrations (1.8 or 3.6 mM) used in this and subsequent studies were those that were previously found to be optimal for SG transfection. 6 Administration of plasmid DNA without added zinc or ATA did not result in plasma SEAP concentrations above the SEAP assay background (50 pg/ml). For all the formulations screened, transgene expression in either plasma or tissue samples was transient, with a maximum observed at 48 h post-DNA administration (data not shown).
The dose effect of plasmid DNA was determined by screening solutions containing 87.5, 175, or 350 mg of plasmid DNA at identical zinc/ATA concentrations in rat SG. The SEAP concentrations in both plasma and submandibular gland tissues increased with DNA dose, with 350 mg of plasmid DNA being approximately 10-fold more effective than 87.5 mg of plasmid DNA (Figure 2 ). Zinc/ATA solutions containing DNA doses above 350 mg did not significantly increase transgene expression (data not shown).
To demonstrate a dose-dependent effect of ATA on SG transfection, solutions containing different concentrations of ATA were formulated with a fixed amount of zinc and plasmid DNA, and administered to submandibular glands. At 48 h after administration, the concentration of SEAP protein in plasma was proportional to the dose of ATA. As shown in Figure 3 , the highest average concentrations of SEAP (190 ng/ml of plasma) were obtained at the highest ATA concentration (12 mg ATA/ml). Substantial swelling and redness of the submandibular glands was observed at the highest ATA concentration, presumably a result of inflammation Figure 1 Effect of zinc and ATA on observed transgene expression after nonviral SG transfection. Plasmid DNA (SEAP, 175 mg/200 ml) solutions containing zinc, ATA (4 mg/ml), or zinc/ATA (4 mg/ml) were administered retroductally to the right and left submandibular glands of adult, male Sprague-Dawley rats. Plasma samples were collected 48 h after plasmid DNA administration and assayed for SEAP concentration. Each data point represents the average value obtained from four animals (7s.e.m.). *Po0.05. Figure 2 Effect of plasmid DNA dose on zinc/ATA SG transfection. Zinc (3.6 mM)/ATA (4 mg/ml) solutions (100 ml) containing 87.5, 175, or 350 mg of plasmid DNA (SEAP) were administered to the right and left submandibular glands of adult, male Sprague-Dawley rats. Plasma (light gray bars) and submandibular gland tissue (dark gray bars) samples were collected 48 h after plasmid DNA administration and assayed for SEAP concentration. Each data point represents the average value obtained from four animals (7s.e.m.). *Po0.05. Figure 3 Effect of ATA concentration on zinc/ATA SG transfection. Plasmid DNA (SEAP, 300 mg/50 ml) solutions containing 3.6 mM zinc chloride and ATA, at concentrations of 0, 4, 8, or 12 mg/ml, were administered retroductally to the right and left submandibular glands of adult, male Sprague-Dawley rats. Plasma samples were collected 48 h after plasmid DNA administration and assayed for SEAP concentration. Each data point represents the average value obtained from four animals (7s.e.m.). *Po0.05.
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(data not shown). To avoid this response to the treatment, concentrations of ATA above 12 mg/ml were not investigated. In addition, ATA concentrations of either 6 or 8 mg/ml were used in the subsequent studies.
Administration of zinc/ATA/DNA solutions results in higher concentrations of plasmid DNA in SG tissues
The zinc/ATA effect was analyzed using quantitative PCR (qPCR) to determine the relative concentrations of plasmid DNA in SG tissues following retroductal administration of DNA, zinc/DNA, ATA/DNA, or zinc/ATA/DNA solutions. The increase in the amount of tissue-associated plasmid DNA correlates well with the observed levels of SEAP expression with zinc/ATA/ DNA4ATA/DNA4zinc/DNA4DNA ( Figure 4 ). The concentration of plasmid DNA in glands treated with zinc/ATA/DNA was approximately 500 times greater than that in glands treated with plasmid DNA in saline. These data indicate that the observed increase in transgene expression is a result of increased concentration of DNA in the SG.
Zinc/ATA solutions are potent inhibitors of DNA degradation
A series of DNA degradation studies were performed to investigate the effect of zinc/ATA on nuclease activity. Formulations of DNA, zinc/DNA, ATA/DNA, or zinc/ ATA/DNA were each incubated with DNase I and DNase II. In addition, these formulations were incubated with rat submandibular gland lysates. DNA integrity was then analyzed by agarose gel electrophoresis. As shown in Figure 5 , zinc and zinc/ATA were more effective in protecting DNA from DNase I than ATA only, while ATA and zinc/ATA were more effective in protecting DNA from DNase II than zinc only. ATA and zinc/ATA protected DNA from endogenous DNase activity in submandibular gland lysates. These results demonstrate that a mixture of zinc and ATA is a potent general inhibitor of DNases. It should be noted that the amounts of DNase I and DNase II used in this study are different from the amounts of these enzymes found in the submandibular gland lysate.
Zinc/ATA/DNA solutions can be administered to the SG without detectable inflammation
Histological examination of the submandibular gland tissue revealed that treatment of SG with either a DNAonly or zinc/DNA formulation looked normal compared to untreated tissues (data not shown). However, inflammatory infiltrates were observed both in the SG connective tissue and capsule, and edematous changes were observed in the parenchyma after treatment with zinc/ATA/DNA (Figure 6a ). This observed inflammation was alleviated by treating the animals with dexamethasone prior to DNA administration. An intramuscular injection of dexamethasone (1.5 mg/kg bodyweight) immediately prior to the administration of Figure 4 qPCR analysis of SG tissues. Plasmid DNA (SEAP, 300 mg/ 50 ml) solutions containing zinc, ATA (8 mg/ml), or zinc/ATA (8 mg/ml) were administered retroductally to the right and left submandibular glands of adult, male Sprague-Dawley rats. Submandibular gland tissues were collected 48 h after administration and the tissue-associated DNA was extracted and purified. The amount of plasmid DNA was quantified by qPCR, and concentrations are presented as copies of plasmid DNA per 100 ng genomic DNA. Each data point represents the average value obtained from six samples (7s.e.m.). *Po0.05. Note: Background value for untreated SG tissue is 53716 copies of plasmid DNA per 100 ng of genomic DNA. Enhanced salivary gland transfection EJ Niedzinski et al the zinc/ATA/DNA solution resulted in no detectable inflammation at 2 or 8 days after administration of the zinc/ATA/DNA formulation (Figure 6b and c) . Pretreatment with dexamethasone did not have a detrimental effect on observed transgene expression (data not shown). The acini remained intact and no structural or edematous changes were observed. The presence of small intracellular vacuoles suggests that the secretory process was not affected by administering the zinc/ ATA/DNA formulation after dexamethasone pretreatment. These results indicate that zinc/ATA/DNA formulations can be administered to the SG without detectable adverse effects.
Discussion
Systemic secretion of SEAP protein was observed after retrograde administration of plasmid DNA formulations containing zinc, ATA, or a combination of zinc and ATA.
The highest systemic levels of SEAP (B0.3 mg/ml) were observed following administration of the zinc/ATA/ DNA solution, likely a result of a synergistic zinc-ATA effect on transfection. The amount of SEAP protein in plasma was found to be dependent on the amount of zinc, ATA, and plasmid DNA contained in the administered formulation. The relative ability of zinc, ATA, and zinc/ATA to enhance systemic SEAP expression is associated with the ability of these adjuvants to increase the amount of tissue-associated plasmid DNA, suggesting that an increase in transfection efficacy is responsible for the observed increase in transgene expression. We believe that endonuclease degradation of plasmid DNA is a barrier to efficient SGs transfection. It has been shown that these glands are rich in DNase content. 11, 12 A detailed distribution analysis in rats revealed that SGs have higher DNase concentrations than the pancreas, kidney, liver, spleen, lung, stomach, small and large intestine, and thymus. 12 While the relative DNase concentrations in these organs are species-dependent, SGs always possess levels of DNase activity. Given our preferred route of plasmid DNA administration to the SG by retroductal perfusion, extracellular and intracellular nucleases most likely affect transfection efficiency. Plasmid DNA administered in this manner could encounter extracellular nucleases in saliva. Rat parotid gland saliva is known to contain significant concentrations of DNases. 13 After surviving the extracellular nucleases, administered DNA could then be subjected to a gauntlet of lysosomal and cystolic endonucleases before entering the nucleus.
Endonuclease degradation is suspected to be a substantial barrier to efficient plasmid DNA transfection in tissues other than the SG. 14, 15 For example, GlasspoolMalone et al 16 provided evidence suggesting that plasmid DNA is readily degraded in respiratory fluids by extracellular endonucleases. Studies have also shown the potentially deleterious effects of intracellular endonucleases on transfection efficacy. [17] [18] [19] Specific inhibitors of pH-sensitive DNases have been shown to enhance cell transfection. 17 Besides confronting lysosomal nucleases, plasmid DNA may also encounter cytosolic nucleases prior to nuclear uptake. Based on studies performed in HeLa and COS cells, the estimated half-life of plasmid DNA in cytosolic fluids is approximately 50-90 min. 20 In general, the presence of intracellular nucleases may be responsible for an observation, suggesting that only one out of 1000 plasmid DNA copies is effectively trafficked to the nucleus. 19 Since the deleterious effect of nucleases appears to be widespread, strategies directed at improving SG transfection efficacy by overcoming this barrier may have broad implications.
We decided to use zinc and ATA in our SG transfection studies because both are known to be potent endonuclease inhibitors. Zinc is particularly effective at inhibiting calcium-and magnesium-dependent endonucleases, like DNase I, while ATA is a more general nuclease inhibitor, capable of DNase I and DNase II inhibition. 21, 22 Recent studies in our laboratories and others demonstrate that zinc can be used to enhance plasmid DNA transfection with or without the addition of other transfection enhancers. 6, 10 We observed that zinc enhanced both transgene expression and accumulation of plasmid DNA in SG tissues. 23 Reports by others have shown that ATA alone is effective at both inhibiting endogenous nucleases and enhancing in vivo and in vitro transfection efficacy. [14] [15] [16] 19 In the current study, ATA and a combination of zinc and ATA were more effective at promoting systemic transgene expression and accumulation of plasmid DNA in tissues than zinc alone, thus highlighting the potential importance of general nuclease inhibitors in SG transfection. The zinc/ATA mixture was found to be a more potent general endonuclease inhibitor than ATA alone, by virtue of the enhanced inhibition of DNase I activity. When considered in concert, the correlations between transgene expression, tissue plasmid DNA accumulation, and DNase inhibitory activity observed after using the zinc/ATA formulation strongly support our hypothesis that nucleases are a substantial barrier to efficient SG transfection that can be effectively overcome by using general nuclease inhibitors.
A published report by Glasspool-Malone et al 14 mentions that pulmonary administration of ATA doses 42 mg/g body weight can be lethal in mice. In our study using SG administration in rats, no deaths were observed at the highest ATA dose examined (approximately 7 mg/ g body weight). We found that treatment of SGs with zinc/ATA/DNA elicits an acute inflammatory response within 2 days of administration, a possible indication of direct formulation toxicity. Pretreatment with dexamethasone, a glucocorticoid, effectively mitigated this inflammatory response for the duration of the experiment (8 days). It is of interest to note that others have observed a similar acute inflammatory response in SG tissues when treated with adenoviral vectors. 24 In this case, the inflammation was attributed to direct viral toxicity. As noted with the zinc/ATA/DNA formulation, adenoviral-induced inflammation can also be suppressed with dexamethasone pretreatment. 24 Dexamethasone is a safe, potent, anti-inflammatory drug that could potentially be used in conjunction with zinc/ATA/DNA in a clinical setting. However, it is our interest to further enhance the transfection efficiency of zinc/ATA/DNA formulations so that smaller, potentially less toxic, doses can be used to provide the desired therapeutic effect without the need for systemic dexamethasone treatment; appropriate studies are currently underway in our laboratories.
In summary, mixtures of zinc and ATA improved systemic transgene expression after nonviral gene transEnhanced salivary gland transfection EJ Niedzinski et al fer to the SGs by at least three orders of magnitude relative to naked DNA treatment. This enhancement in expression was associated with an increased plasmid DNA concentration in SG tissues. Zinc/ATA solutions were shown to be effective at preventing plasmid DNA degradation in solutions containing DNase I, DNase II, and whole SG lysates, suggesting that plasmid DNA degradation may be a barrier to efficient SG transfection.
Materials and methods

Materials
Anhydrous zinc chloride (97%) was purchased from Aldrich Chemical Company (Milwaukee, WI, USA). Aurintricarboxylic acid, triammonium salt (ATA) and dexamethasone were obtained from Sigma (St Louis, MO, USA). DNase I and DNase II extracts were obtained from Worthington Biochemical (Lakewood, NJ, USA).
Preparation and purification of reporter genes
The plasmid pBATSEAP contains the SEAP gene operably linked to human cytomegalovirus major immediate-early enhancer/promoter, which is positioned upstream of the first intron of human b-globin. pBATS-RUC is a similar plasmid except that it contains the renilla luciferase gene in lieu of the SEAP gene. Both plasmid vectors were produced by bacterial fermentation and purified with an anion exchange resin (Qiagen, Santa Clarita, CA, USA) to yield an endotoxin-reduced, supercoiled plasmid containing less than 100 E.U./mg DNA as measured by clot LAL assay (Charles River Endosafe). Stock DNA solutions were prepared using sterile water.
Preparation of ATA/DNA and Zinc/ATA/DNA solutions For, ATA/DNA solutions, the requisite amounts of 0.9% sterile saline, ATA, and plasmid DNA were sequentially added to polystyrene tubes, vortexed, and allowed to stand for at least 10 min at room temperature prior to administration to the rat submandibular glands. Zinc/ ATA/DNA solutions were formed in a similar manner, except that the requisite amount of zinc chloride was added prior to the addition of plasmid DNA.
Administration of DNA solutions to rat SGs
Male Sprague-Dawley rats (260-280 g, Harlan Laboratories, San Diego, CA, USA) were fasted the night prior to treatment. After intramuscular administration of a mixture of ketamine (30 mg/kg body weight), xylazine (6.0 mg/kg body weight), and acepromazine (1.0 mg/kg body weight ), both the right and left Wharton's ducts were cannulated with fine polyethylene tubing (i.d. 0.011 00 ) and cemented in place with a quick drying adhesive. Atropine (0.5 mg/kg body weight) was then administered subcutaneously and, after 10 min, the plasmid DNA solution was administered through the tubing. The tubing was then removed 10 min later. When indicated, dexamethasone (1.5 mg/kg body weight) was administered via intramuscular injection immediately prior to DNA administration. At 48 h post-DNA administration, the rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight). Plasma was collected from heparinized whole blood by cardiac puncture and stored at À801C until assay. The right and left submandibular glands were surgically excised, homogenized at 01C in 15 volumes of Pharmingen's luciferase lysis buffer (San Diego, CA, USA) or phosphate-buffered saline (PBS), and centrifuged at 41C for 20 min. The supernatants were collected and frozen at À801C until assay. All research conducted using these experimental animals adhered to the 'Principle of Laboratory Animal Care' (NIH publication #85-23, revised in 1985).
Histology
At 48 h after administration of the formulation, the left and right submandibular glands were removed and immediately bisected. The tissues were then placed in 10% neutral-buffered formalin. They were shipped to a reference lab (Histopathology Reference Laboratory, Richmond, CA, USA) for routine tissue processing and paraffin embedding. The resulting H&E stained slides were visualized on a Zeiss Axiovert 100 microscope and photographed with a Kodak DC290 digital camera.
Secreted alkaline phosphatase assay
Tissue supernatants, prepared in luciferase lysis buffer, were analyzed for SEAP concentration using the chemiluminescent SEAP Reporter Gene Assay available from Roche Diagnostics (Indianapolis, IN, USA). Briefly, the samples were diluted 1:50 with dilution buffer, then incubated in a water bath for 30 min at 651C. The samples were then centrifuged for 1 min at 13 000 r.p.m., and 50 ml of the resulting supernatant was transferred to a microtiter plate. A total of 50 ml of the provided inactivation buffer was added followed by a 5-min incubation at room temperature. The substrate reagent (50 ml) was added prior to a 10-min incubation at room temperature. Light emissions from the samples were measured using an L-max plate luminometer from Molecular Devices (Sunnyvale, CA, USA). The relative light units were converted to mass of SEAP protein based on a standard curve run contemporaneously with the samples. Plasma concentrations of SEAP were measured using the same assay except that the samples were diluted 1:7 with the dilution buffer. The lower sensitivity limit for determining SEAP protein concentrations in rat plasma is 50 pg/ml.
Quantitative PCR analysis
DNA was extracted from tissues using the DNeasy Kit (Qiagen, Valencia, CA, USA) as per the manufacturer's instructions. The concentration of DNA purified from tissues was quantified by using the DNA minor groove binding PicoGreen Assay (Molecular Probes, Eugene, OR, USA). Samples were stored at À201C until assayed. The amplification reactions were performed in a 50 ml final volume containing 1 Â Supermix UDG (Invitrogen, San Diego, CA, USA), forward and reverse primers, fluorescently labeled probe, and 10 ng genomic DNA. For the SEAP reporter gene plasmid DNA (pBATSEAP), 1 Â forward and reverse primers and 1 Â TaqMan probe (Applied Biosystems, Foster City, CA, USA) was added to the PCR mix. Thermal cycling conditions were 1 min at 541C followed by 10 min at 951C and 45 cycles of 1 min at 951C and 1 min at 601C (Applied Biosystems ABI7700). The standard curve was generated by the addition of DNA into liver genomic DNA. DNA was subjected to amplification by PCR using primers specific for the SEAP 
DNA protection assay
This assay was performed using procedures similar to those described by Campbell and Jackson. 25 Briefly, stock DNase I and DNase II solutions were prepared in the appropriate buffers at concentrations of 0.4 and 2 milliunits/ml, respectively. The tissue supernatants, prepared in PBS, were further diluted by a factor of 1:10 with PBS. Plasmid DNA (pBATSRUC) was combined with either 3.6 mM ZnCl 2 , a mixture containing 0.15 mM ZnCl 2 , and 0.67 mg/ml ATA, or 0.67 mg/ml ATA to give a final plasmid DNA concentration of 0.1 mg/ml. At 01C, 10 ml aliquots of the plasmid DNA solutions7adjuvants were mixed with 20 ml of the appropriate DNase solution or diluted SG lysate. The resultant mixtures were incubated for 5 min at 371C prior to the addition of sample loading buffer and being electrophoresed on a 0.7% (w/v) agarose gel.
Statistical analysis
Statistical analysis was performed using the Student's t-test.
